lp-a.org

Trial

Lp(a)HORIZON

Novartis (pelacarsen, TQJ230) · 12 December 2019

Status Completed; neutral result presented at AHA 2026 and published in NEJM, 7 November 2026

The first cardiovascular outcomes trial of any Lp(a)-lowering therapy, and a neutral one: 8,350 patients with prior myocardial infarction, ischaemic stroke or symptomatic peripheral artery disease and Lp(a) of 70 mg/dL (about 149 nmol/L) or more were randomised to monthly subcutaneous pelacarsen 80 mg or placebo (8,322 in the efficacy analysis). Lp(a) fell to a median 64.4 versus 233.4 nmol/L at 12 months, about 78 percent, yet over a median 4.7 years the primary endpoint occurred in 12.3 versus 12.1 percent (hazard ratio 1.02, 95 percent CI 0.90 to 1.15, P=0.76), with no effect in the prespecified subgroup with Lp(a) of 90 mg/dL or more (hazard ratio 1.00). Presented in the late-breaking session LBS.01 at AHA Scientific Sessions 2026 on 7 November and published simultaneously in NEJM (Cho, Nicholls, Frndak et al.), with extended analyses in NEJM Evidence.

Design. Phase 3, randomised, double-blind, placebo-controlled, 797 sites in 42 countries; 1:1 to pelacarsen 80 mg every 4 weeks or placebo on optimised standard of care (median LDL-C 64.6 mg/dL, 77.6 percent on a high-intensity statin); primary endpoint time to first MACE (CV death, non-fatal MI, non-fatal stroke, urgent coronary revascularisation), with a second primary analysis in patients with Lp(a) of 90 mg/dL or more. Started December 2019, enrolment completed 2022. Design paper: Cho, Nicholls, Nordestgaard et al., Am Heart J 2025.

Result (NEJM, 7 November 2026). Mean age 59.7 years, 27 percent women, median baseline Lp(a) 236 nmol/L. Primary endpoint 511 of 4,157 (12.3 percent) on pelacarsen versus 503 of 4,165 (12.1 percent) on placebo, hazard ratio 1.02 (0.90 to 1.15), P=0.76; Lp(a) of 90 mg/dL or more: 402 of 3,266 versus 403 of 3,274 (both 12.3 percent), hazard ratio 1.00 (0.87 to 1.15). Serious adverse events 37.3 versus 41.1 percent. The investigators reported no signal in any subgroup or secondary endpoint; the extended analyses are in NEJM Evidence. Senior author Steven Nissen at the presentation: "It didn't work."

Why it matters. Mendelian randomisation says about 65 to 100 mg/dL of Lp(a) lowering should equal 1 mmol/L of LDL-C lowering, and pelacarsen delivered about 78 percent lowering from these baselines, so the neutral result sends the field back to the mechanisms. The explanations under discussion: lifelong exposure already fixed in the arterial wall, a very well treated population with little residual risk to remove, and a follow-up of under five years against a genetic instrument that measures a lifetime. The siRNA outcomes trials (OCEAN(a)-Outcomes, ACCLAIM-Lp(a)) and the oral muvalaplin trial (MOVE-Lp(a)) continue; their deeper lowering is now the hypothesis under test. Measuring Lp(a) once in a lifetime remains guideline advice for risk stratification.

Companion trials. Lp(a)FRONTIERS APHERESIS (NCT05305664, published EHJ 2026): pelacarsen replaced weekly apheresis in 25 of 26 German patients. Lp(a)FRONTIERS EXPANSION (NCT06267560, 423 US Black/African American and Hispanic participants): 86 percent placebo-adjusted Lp(a) lowering at week 52, presented at AHA 2026 and published in Circulation: Population Health and Outcomes. Lp(a)FRONTIERS CVD (NCT05646381, phase 2, n=502, running to 2030); pelacarsen with background inclisiran (NCT06813911); open-label extensions (NCT05900141, NCT06875973, NCT07517263).

Videos. Steven Nissen discusses the result with Harriette Van Spall, and sums up the take-home messages, in two Radcliffe Cardiology interviews on our video pages.

ClinicalTrials.gov

outcomes trialpelacarsenphase 3secondary prevention

Page updated 10 November 2026.